Can a fractional CRO fix a stalled sales pipeline at a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Healthcare Technology Buying Committee Is a Five-to-Nine-Person Cross-Functional Wall

In a healthcare technology company selling to hospitals, health systems, or large physician groups, the buying committee includes a clinical champion (typically a physician informaticist, chief medical information officer, or nurse director who validates workflow fit), an IT security officer (who demands SOC 2 Type II reports, HITRUST certification, penetration test results, and a completed CAIQ or SIG questionnaire), a compliance officer (who checks for HIPAA BAAs, data residency requirements, FDA clearance for diagnostic tools, or state-specific telehealth regulations), a finance lead (often a VP of Revenue Cycle or CFO who evaluates total cost of ownership including implementation fees and ongoing support), an executive sponsor (CMO, COO, or sometimes the CEO for deals above $500,000), and a procurement specialist (who manages the RFP process and vendor credentialing). The typical deal size for a single hospital system or large practice group ranges from $100,000 to $1.5 million in annual contract value, while enterprise-wide deals for multi-hospital networks or integrated delivery networks (IDNs) land at $500,000 to $5 million with multi-year commitments. Budget approval requires a capital expenditure request that needs board-level sign-off for anything above $250,000, and the procurement cycle includes a mandatory legal review of business associate agreements (BAAs) that takes six to twelve weeks, plus a vendor credentialing process that requires submitting financial statements, liability insurance certificates, proof of past implementations, and references from similarly sized organizations. Deals most often stall at two specific points: the IT security review, where the buyer demands evidence of penetration testing, subprocessor lists, and data encryption standards that the vendor has not prepared, and the clinical validation stage, where the champion cannot secure time with frontline staff to run a pilot or observe workflow integration because the vendor lacks a clear implementation playbook. The buyer evaluates not just product features but the vendor's ability to demonstrate interoperability with existing EHR systems (Epic, Cerner, Meditech, or Allscripts), adherence to HL7 FHIR standards, a track record of successful implementations in similarly sized organizations, and the vendor's financial stability to ensure they will still exist in three years. A fractional CRO who has never navigated a hospital system's vendor credentialing process or a group purchasing organization (GPO) contracting cycle will fail here because the buying dynamics are non-negotiable and industry-specific.

The Sales Cycle Forces a "Two-Step" Motion That Breaks Standard Forecasting and Pipeline Metrics

Healthcare technology sales cycles run nine to eighteen months, with the first three to six months spent purely on education and trust-building before any formal evaluation begins, because the buyer must first understand how the product fits into existing clinical workflows and whether it will require changes to how physicians and nurses operate. The motion is not a linear SaaS pipeline but a two-step process: first, the vendor must be added to the health system's "approved vendor list" through a credentialing process that can involve submitting financial statements, liability insurance certificates, proof of past implementations, and references from similarly sized organizations; second, only then does the actual sales cycle start with a request for proposal (RFP) or proof-of-concept that requires the vendor to demonstrate integration with the health system's specific EHR instance. This two-step structure forces a pipeline shape where 60 to 70 percent of opportunities sit in a "pre-qualified" stage for months, generating zero revenue but consuming sales resource time on credentialing paperwork and security questionnaires. Ramp time for a new sales hire is twelve to eighteen months because they must build relationships with clinical champions and IT gatekeepers simultaneously, learn the specific regulatory requirements for each state the vendor operates in, and understand the nuances of different EHR integrations. The first two quarters typically yield no closed deals, which means any fractional CRO who inherits a team with less than six months of tenure knows the pipeline is likely inflated with early-stage opportunities that have no path to close. Forecast behavior is notoriously unreliable: a deal that looks "90 percent likely" in a standard B2B pipeline because the champion loves the product can evaporate when the IT security officer flags a subprocessor in a foreign jurisdiction or the compliance team discovers the vendor lacks a specific ONC certification for interoperability. The leaks are concentrated in the middle of the funnel: after the RFP is submitted, the buyer goes silent for four to eight weeks while their legal team reviews the BAA, and that silence often kills momentum because the clinical champion who drove the deal moves to another project. A fractional CRO who tries to apply a standard "accelerate the pipeline" playbook - discounting, free trials, executive engagement - will actually slow the cycle because healthcare buyers interpret urgency as desperation and discounting as a sign of weak product-market fit. The correct intervention is to install a rigorous stage-gate process that separates "clinical validation" from "contracting" and assigns different owners to each, with the fractional CRO personally managing the transition between gates.

The First 90 Days of a Fractional Healthcare Tech CRO: Diagnose the Stall Type, Not the Pipeline Size

A fractional CRO walking into a stalled healthcare technology pipeline must spend the first 30 days doing a forensic audit of the three most common stall types specific to this industry: (1) top-of-funnel stall caused by insufficient volume of qualified leads from health systems, where the sales team is chasing small clinics or private practices that cannot afford the product or lack the regulatory sophistication to evaluate it; (2) middle-of-funnel stall caused by failure to pass IT security or clinical validation gates, where deals have been in "evaluation" for more than 90 days without a documented security questionnaire submission or clinical pilot schedule; and (3) bottom-of-funnel stall caused by procurement delays in legal or contracting, where deals have been in "legal review" for more than 60 days without a signed BAA. The audit requires interviewing the existing sales team (typically three to six reps who may have been hired for their relationships with hospital administrators rather than their ability to navigate procurement), reviewing the last 20 lost deals for common rejection patterns (competitor had better Epic integration, vendor lacked HITRUST certification, product required too much workflow change), and mapping the current pipeline against the buyer's actual decision timeline - not the CRM's probability field, which in healthcare tech is almost always inflated by 20 to 30 percent. In days 31 to 60, the fractional CRO implements targeted fixes: for top-of-funnel stall, they shift from outbound cold calling (which fails in healthcare because decision-makers are shielded by gatekeepers and rarely answer unsolicited calls) to a referral-based or conference-driven sourcing strategy targeting health system CMOs and CIOs at HIMSS, ViVE, CHIME, or regional health IT symposiums where the fractional CRO personally attends and schedules meetings. For middle-of-funnel stall, they create a "clinical validation package" that includes a one-page summary of how the product fits into existing EHR workflows (specific to Epic, Cerner, or Meditech), a pre-completed security questionnaire (HITRUST or CAIQ format), and a reference list of three similar health systems that have already deployed the solution with named contacts the buyer can call. For bottom-of-funnel stall, they assign a dedicated "contracting navigator" (often a fractional legal or compliance consultant who has negotiated BAAs before) who pre-negotiates the BAA before the deal enters legal, cutting procurement time by 30 to 50 percent by resolving the most common objections (data residency, subprocessor lists, indemnification clauses) upfront. In days 61 to 90, the fractional CRO builds a 90-day pipeline forecast that uses "committed dates for clinical pilot completion" and "BAA submission date" as leading indicators, not the CRM's weighted probability, and they stop reporting deals that lack both a clinical champion and a documented IT security review date. They also establish a weekly operating cadence of a 30-minute pipeline review every Monday focused on stage-gate movement (did the deal move from clinical interest to IT security review? did the BAA get submitted?) and a 60-minute strategy session every Thursday focused on one specific stalled deal with the CEO and VP of Product attending to decide whether to invest in a custom integration or accept a longer sales cycle. The fractional CRO owns the sales process, team management, and pipeline hygiene, but advises on product roadmap prioritization (which interoperability standards to support next, whether to pursue HITRUST certification) and marketing messaging (whether to lead with clinical outcomes for the CMO or cost savings for the CFO).

What the Fractional CRO Owns vs. Advises On in Healthcare Technology

The fractional CRO must own the sales process end-to-end: hiring and firing sales reps, setting compensation plans (typically a 50/50 base-to-variable split with a 12-month ramp guarantee because healthcare tech cycles are too long for a 90-day ramp), managing the CRM (HubSpot or Salesforce with custom stage-gate fields for clinical validation, IT security review, and BAA submission), and running forecast calls that exclude any deal without a documented next gate date. They own the deal desk, approving discounts (which should be rare in healthcare tech because price sensitivity is low but compliance sensitivity is high, and discounting signals weak product-market fit to procurement teams) and setting contract terms (payment milestones tied to go-live dates and specific integration milestones, not annual prepayments). They own the sales team's training on healthcare-specific topics: how to talk to IT security officers about data encryption and subprocessor management, how to present clinical workflow integration to physicians, and how to navigate the RFP process without giving away pricing too early. They advise on product positioning: whether to emphasize clinical workflow efficiency for the CMO, revenue cycle improvement for the CFO, data security for the IT officer, or regulatory compliance for the compliance officer, and how to create separate one-pagers for each buyer persona. They advise on marketing spend: whether to invest in content marketing (white papers on interoperability standards or case studies with named health systems that have signed reference agreements) or demand generation (sponsored sessions at regional health IT events where the fractional CRO personally presents). They advise on partner strategy: whether to pursue a reseller agreement with a major EHR vendor like Epic or Cerner (which takes 12 to 18 months to negotiate and requires significant integration investment) or a referral arrangement with a GPO like Vizient or Premier (which can be faster but yields lower margins and requires GPO contract approval). The fractional CRO does not own product development, customer success (though they must align with it to ensure implementations are smooth and referenceable), or regulatory filings (FDA 510(k), ONC certification, state telehealth licenses). The signal to convert to full-time is when the pipeline consistently produces three to five qualified opportunities per month with clinical validation completed and BAAs submitted, the sales team has grown to eight or more reps, and the company has achieved at least two referenceable implementations that the fractional CRO can point to in future deals. The signal not to convert is when the core product requires a major regulatory clearance like FDA 510(k) for a diagnostic tool or ONC certification for an EHR module before it can be sold to the target buyer segment, because a full-time CRO cannot accelerate that timeline and the fractional engagement should focus on building pipeline for when clearance arrives.

The Operating Cadence: Weekly, Monthly, Quarterly in Healthcare Technology

The weekly cadence includes a Monday 30-minute "pipeline pulse" where the fractional CRO reviews the top five deals by dollar value, checking specifically whether each deal has moved from "clinical interest" to "IT security review" to "legal review" in the CRM, and flagging any deal that has been in the same stage for more than 30 days without a documented next meeting. Each deal must have a documented "next gate" (clinical pilot scheduled, security questionnaire submitted, BAA sent to legal) and a specific date for the next meeting with the buyer's committee, not just a vague "follow up next week." Thursday includes a 60-minute "deal strategy" session where the fractional CRO, CEO, and VP Product review one stalled deal in depth, focusing on whether the stall is due to a missing certification (HITRUST, ONC, FDA), a competitor's existing relationship with the health system's IT department, or a budget freeze that requires waiting for the next fiscal year. The monthly cadence includes a 90-minute "pipeline review" with the board or investors, showing not just dollar amounts but stage-gate conversion rates: how many leads become clinical pilots, how many pilots become approved vendors, how many approved vendors become signed contracts, and the average time at each stage. The quarterly cadence includes a 4-hour "go-to-market offsite" where the fractional CRO presents a "stall audit" for the prior quarter, identifying the top three reasons deals were lost (competitor had better Epic integration, vendor lacked HITRUST certification, product required too much workflow change for nurses) and proposing specific fixes (hire a part-time integration specialist, complete the HITRUST assessment in Q2, create a workflow change management package for nursing directors). The fractional CRO also maintains a "red flag log" of deals that have been in legal review for more than 60 days, because in healthcare tech, legal delays beyond 60 days indicate the buyer's procurement team has deprioritized the deal, not that they are still negotiating, and the fractional CRO must personally call the buyer's legal contact to determine whether to escalate or kill the deal.

Signals That the Pipeline Is Truly Fixed vs. Temporarily Patched in Healthcare Technology

A fixed pipeline in healthcare technology shows three concrete signals: (1) the ratio of "clinical validation completed" to "BAA submitted" reaches 80 percent or higher, meaning most deals that pass the clinical stage move to legal without stalling at IT security or compliance review; (2) the time from initial meeting to signed contract drops below nine months for deals under $500,000 and below twelve months for deals above $1 million, indicating that the stage-gate process is working and the team knows how to navigate procurement; and (3) the sales team can accurately predict which deals will close in the next quarter because they have two specific data points - the clinical pilot completion date and the BAA submission date - that correlate to a 70 percent win rate based on the company's historical data. A temporary patch shows these signals: the pipeline looks fuller because the fractional CRO added early-stage deals from conferences, but those deals are not moving through the stage gates because they lack clinical champions or IT security contacts; the sales team is logging more activity (calls, emails, meetings) but the number of deals in "legal review" stays flat; or the CEO reports "strong pipeline" to the board but the CFO reports "no new contracts signed" for two consecutive quarters. The fractional CRO must also watch for a specific healthcare tech trap: the "pilot trap" where a health system agrees to a free pilot but never signs a contract because the pilot is treated as an indefinite evaluation with no deadline or decision criteria. If more than 30 percent of the pipeline is in "pilot" status without a signed contract or a specific date for contract decision, the fractional CRO should cut those deals from the forecast and reclassify them as "exploratory" to avoid false pipeline inflation, and should establish a rule that any pilot lasting more than 90 days without a signed contract requires executive escalation to the health system's COO.

FAQ

How long does a fractional CRO typically need to turn around a stalled healthcare technology pipeline? Six to nine months is the realistic timeline because the first two months are diagnostic (auditing lost deals, interviewing the team, mapping the pipeline against buyer timelines), the next three months implement stage-gate fixes (creating clinical validation packages, pre-negotiating BAAs, shifting sourcing strategy to conferences and referrals), and the final month shows whether those fixes produce closed deals. Healthcare tech cycles are too long for a 90-day miracle; any fractional CRO promising results in one quarter is either ignorant of the industry or inflating early-stage pipeline metrics by counting conference leads as qualified opportunities. The true test comes at month nine, when deals that entered the pipeline at month three should be closing, and the fractional CRO can show a measurable reduction in time from clinical validation to BAA submission.

What is the biggest mistake a fractional CRO makes when entering a healthcare technology company? Assuming the sales team's pipeline data is accurate. In healthcare tech, reps often inflate deal stages because they are evaluated on pipeline value, not stage-gate progression, and they may mark a deal as "verbal commitment" when they have only spoken to a clinical champion who has no budget authority or procurement influence. The fractional CRO must personally validate the top five deals by calling the buyer's IT security officer and legal contact - not just the champion - before trusting the CRM, because a deal that looks like a sure thing based on the champion's enthusiasm can evaporate when the security questionnaire reveals a data residency issue or the legal team flags a missing subprocessor disclosure.

Should the fractional CRO focus on outbound sales or inbound marketing for healthcare technology? Neither in isolation. Outbound cold calling fails because health system decision-makers are shielded by administrative assistants, rarely answer unsolicited calls, and have formal vendor intake processes that require submission through a website or portal. Inbound marketing fails because healthcare buyers do not self-educate through generic content; they want peer referrals from other health system leaders and conference interactions where they can see the product demonstrated in a clinical context. The correct approach is a "trusted referral" motion where the fractional CRO builds relationships with health system CIOs and CMOs through industry events (HIMSS, CHIME, ViVE, regional health IT symposiums) and asks for introductions to their peers at other systems, then follows up with a pre-completed security questionnaire and clinical workflow summary to accelerate the credentialing process.

What compensation structure works for a fractional CRO in healthcare technology? A fixed monthly retainer of $18,000 to $30,000 (depending on deal size and company stage) plus a performance bonus of 5 to 10 percent of new annual contract value closed during their engagement, capped at $50,000 to $100,000 per quarter to prevent the fractional CRO from focusing only on large deals that take longer to close. The bonus should be tied to contracts signed with BAAs executed, not pipeline created or meetings booked, to prevent the fractional CRO from inflating early-stage deals that will not close within their engagement. Avoid equity-only arrangements because fractional CROs need cash flow to sustain their practice, and healthcare tech sales cycles are too long to wait for an exit or Series A round that may never materialize.

Sources